Kessler Investment Group LLC Invests $3.51 Million in Hims & Hers Health, Inc. (NYSE:HIMS)

Kessler Investment Group LLC purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 118,728 shares of the company's stock, valued at approximately $3,508,000. Hims & Hers Health makes up about 1.7% of Kessler Investment Group LLC's holdings, making the stock its 25th biggest position. Kessler Investment Group LLC owned approximately 0.05% of Hims & Hers Health at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Perigon Wealth Management LLC lifted its holdings in shares of Hims & Hers Health by 18.1% in the first quarter. Perigon Wealth Management LLC now owns 16,449 shares of the company's stock worth $486,000 after buying an additional 2,521 shares in the last quarter. Global Assets Advisory LLC purchased a new stake in shares of Hims & Hers Health in the first quarter worth about $1,673,000. Yorktown Management & Research Co Inc purchased a new stake in shares of Hims & Hers Health in the first quarter worth about $229,000. Oppenheimer & Co. Inc. increased its position in shares of Hims & Hers Health by 8.5% in the first quarter. Oppenheimer & Co. Inc. now owns 39,289 shares of the company's stock worth $1,161,000 after purchasing an additional 3,079 shares during the last quarter. Finally, Crewe Advisors LLC increased its position in shares of Hims & Hers Health by 105.9% in the first quarter. Crewe Advisors LLC now owns 2,415 shares of the company's stock worth $71,000 after purchasing an additional 1,242 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Up 6.8%

Shares of Hims & Hers Health stock traded up $3.15 on Friday, hitting $49.43. The stock had a trading volume of 83,270,134 shares, compared to its average volume of 23,099,790. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The stock has a market cap of $11.06 billion, a price-to-earnings ratio of 71.63, a PEG ratio of 1.86 and a beta of 2.09. The stock's 50-day simple moving average is $50.09 and its two-hundred day simple moving average is $39.66.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The firm had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. During the same quarter last year, the business earned $0.05 earnings per share. The business's revenue was up 110.7% on a year-over-year basis. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. TD Cowen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $44.00 to $30.00 in a research report on Tuesday, April 29th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research report on Monday, June 23rd. Wall Street Zen upgraded shares of Hims & Hers Health from a "hold" rating to a "buy" rating in a research report on Sunday, June 15th. Truist Financial set a $45.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, June 24th. Finally, Morgan Stanley restated an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $39.58.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 36,460 shares of the firm's stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $28.04, for a total value of $1,022,338.40. Following the completion of the sale, the chief executive officer now owns 92,103 shares of the company's stock, valued at $2,582,568.12. This trade represents a 28.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm's stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $60.22, for a total value of $697,407.82. Following the transaction, the chief financial officer now directly owns 113,816 shares of the company's stock, valued at $6,853,999.52. This represents a 9.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold 706,454 shares of company stock valued at $35,220,112 over the last quarter. 13.71% of the stock is owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.